Cogent Biosciences, Inc. COGT Stock-Based Compensation Expense — Operating Income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cogent Biosciences, Inc.'s stock-based compensation expense — operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cogent Biosciences, Inc.'s stock-based compensation expense — operating income?
- Cogent Biosciences, Inc. (COGT) reported stock-based compensation expense — operating income of $16.91M in Q1 2026.
- How has Cogent Biosciences, Inc.'s stock-based compensation expense — operating income changed year-over-year?
- Cogent Biosciences, Inc.'s stock-based compensation expense — operating income increased by 68.9% year-over-year, from $10.01M to $16.91M.
- What is the long-term trend for Cogent Biosciences, Inc.'s stock-based compensation expense — operating income?
- Over 3 years (2022 to 2025), Cogent Biosciences, Inc.'s stock-based compensation expense — operating income has grown at a 35.9% compound annual growth rate (CAGR), from $18.37M to $46.08M.
- What does stock-based compensation expense — operating income mean?
- This metric represents the portion of total operating losses attributable to non-cash expenses incurred through equity-based awards granted to employees and directors. It highlights the impact of share-based incentive programs on the company's core operational profitability and burn rate. Monitoring this figure helps investors assess how much of the reported operating deficit is driven by compensation strategy rather than direct research and development or administrative cash outflows.